The Screening module captures, integrates, processes, and interprets selection and screening data derived from diverse discovery technologies, including phage and yeast display, B-cell cloning, and hybridoma. Designed to enable fully automated, high-throughput screening of biotherapeutic candidates, it dramatically increases the efficiency of the early discovery process of antibodies, bi- and multi-specifics, fusion proteins, TCRs, CAR-Ts and other new modalities. The system comes with built-in sample tracking via integrated plate management functionalities, which facilitates day-to-day laboratory operations. Its built-in reporting and analysis tools provide clear and transparent selection criteria to identify high-quality leads that can be shared among all relevant teams.
The system captures all relevant screening readouts as well as the applied methods (ELISA, FACS, SPR/Biacore, BLI, FMA etc.), any sequencing data, and all related metadata and experimental protocols.
The Screening module integrates all data by directly interacting with lab automation equipment such as colony pickers and liquid handling systems to enable fully automated high-throughput screening processes.
Scalable tools, able to handle 100,000s of molecules in parallel, automatically annotate all sequences based on many criteria including structure and format information, post-translational modifications, chemical liability motifs, and uniqueness.
Sophisticated tools for hit selection allow users to identify the best hits based on complex criteria and easily connect screening readouts with molecular architecture and sequence characteristics.
All information can be exported in customizable reports to address specific reporting requirements and facilitate efficient data sharing across groups.
The system offers unparalleled flexibility for screening candidates in any protein format including IgGs, ADCs, bi- and multi-specifics, TCRs, as well as screening of cell therapeutics such as CAR-Ts.
1 / 3